AleksandrLombrozo

Cleveland BioLabs is at the bottom of the weekly box

Long
NASDAQ:CBLI   None
Despite reporting $1.9 million net loss for the second quarter of 2016 technical analysis stipulates the shares of the company would at least double its value.
The point is that there was a bullish engulfing at the bottom of a significant rectangle which lasts more than a year. Moreover RSI(5) analysis implies divergence which coupled with double bottom increases the chances a winning trade.
For more ideas visit mercurius.wordpress.com

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.